0 Replies
Stories include:
Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value plays in the months ahead. One reason Simeonidis is focusing on value, he explains, is that there... Contine Reading & Discuss→
0 Replies
Stories include:
Rigel Pharmaceuticals (NASDAQ: RIGL, Market Outperform)
We continue to view RIGL shares as undervalued: the company finished 1Q 2010 with ~$210M in cash and with no debt, and at today's market cap of $437M, has an enterprise value of approximately $227M. The company's lead compound R788, a syk... Contine Reading & Discuss→
0 Replies
Stories include:
With Eisai's patent protection for the Alzheimer's drug Aricept going off patent in November, the Japanese company is looking for a patch version of the drug to help make up for anticipated sales loss to rivals. Eisai may begin patch sales as early as the second quarter of... Contine Reading & Discuss→
0 Replies
Stories include:
Quark Pharmaceuticals, a Fremont, CA-based developer of RNAi-based therapeutics, is collaborating with Nitto Denko, a diversified materials manufacturer based in Osaka, Japan, to develop siRNA therapeutics to treat fibrotic diseases. Quark will provide the RNAi technology and Nitto Denko will work on drug delivery. The two companies are... Contine Reading & Discuss→
0 Replies
Stories include:
Silence Therapeutics is making a lot of noise these days when it comes to taking advantage of key IP and partnerships in the London-based company's RNA interference (RNAi) technology.
The latest is a one-year extension of ongoing research with AstraZeneca. The two companies have worked together since 2007... Contine Reading & Discuss→
0 Replies
Stories include:
The U.S. Department of Defense has recruited a few good nanoparticles from Tekmira Pharmaceuticals to deliver RNAi therapeutics in the fight against the deadly Ebola virus.
Tekmira, based in Vancouver, BC, is developing an siRNA delivery platform it calls SNALP, for "stable nucleic acid-lipid particles." SNALP are specialized... Contine Reading & Discuss→
0 Replies
WORCESTER, Mass., Jul 13, 2010 (BUSINESS WIRE) – RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced that it was awarded an Advanced Technology Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), part of the... Contine Reading & Discuss→
